The results of this study showed that among CCA patients receiving PD-1 inhibitors combination therapy, the irAEs cohort had a higher DCR (90.6% vs 70.4%, P=0.047), longer OS (median OS: 21.2 vs 10.0 months, P<0.001) and PFS (median PFS: 9.0 vs 4.4 months, P=0.003) compared to the non-irAEs cohort. The gene discussed is PDCD1; the disease is cholangiocarcinoma.